Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGPAT2 | O15120 | 2/20 | 0.49 |
| ▸ | XDH | P47989 | 7/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | TYMS | P04818 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21885713 | 0.80 | XDH (0.61) | XDHPABPC1CYP3A4BLMMEN1 | |
| SCHEMBL21884348 | 0.79 | XDH (0.60) | XDHPABPC1CYP3A4BLMMAPT | |
| SCHEMBL21884347 | 0.79 | XDH (0.60) | XDHPABPC1 | |
| SCHEMBL4291570 | 0.72 | HSP90AA1 (0.66) | AGPAT2IDO1MEN1ALDH1A1MAPT | |
| SCHEMBL16753409 | 0.71 | GSK3B (0.48) | AGPAT2XDHIDO1PIM1TYMS | |
| SCHEMBL25367941 | 0.70 | XDH (0.59) | XDHCYP3A4BLMTYMSMEN1 | |
| SCHEMBL14920216 | 0.69 | AGPAT2 (0.50) | AGPAT2IDO1PIM1MEN1ALDH1A1 | |
| SCHEMBL3277693 | 0.69 | ALDH1A1 (0.61) | AGPAT2IDO1PIM1ALDH1A1MAPT | |
| SCHEMBL14920005 | 0.69 | HTR3E (0.53) | AGPAT2IDO1PIM1TYMSMEN1 | |
| SCHEMBL4142364 | 0.68 | XDH (0.61) | XDHCYP3A4BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371403-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS INC. | 2021-12-02 | — | — | US | disclosed |
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | JNANA THERAPEUTICS INC. | 2021-09-30 | — | — | US | disclosed |
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | JNANA THERAPEUTICS INC. | 2021-09-30 | — | — | US | disclosed |
| WO-2020061473-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | SLC19A1, SLC1A5, SLC1A2 | AGPAT2 313/4885XDH 1075/4885IDO1 4441/4885 |
| US-20210371403-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | SNRPE, G3BP1, G3BP2 | AGPAT2 3922/4885XDH 4012/4885IDO1 4808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.